This pain-free screening method aims to replace the conventional, often harmful X-ray examination and helps to diagnose breast cancer in both younger and older women at an earlier stage than is currently the case.

The development of Delseni and the market launch of the product was made possible by a joint financial impulse from Chemelot Ventures, GMK (a Swiss consultancy and investment company), Rabo Kickstart Venlo, and LIOF.

Current breast cancer research

One in eight women worldwide will be diagnosed with breast cancer in the course of their life. In 1990, the Netherlands introduced the ‘national breast cancer examination’ (bevolkingsonderzoek borstkanker) that invites all women aged between 50 and 75 to be screened for breast cancer every two years by means of a mammography. However, this approach has two drawbacks. Firstly, women under 50 tend to have very high tissue density in the breast area, which can distort the results of a mammography. Secondly, alongside potential pain during the examination, the harmful X-rays may have an adverse effect on patients’ health.

‘Delseni’: a new screening method

In response to this problem, Mito Medical Products has developed ‘Delseni’. Measuring vascularity (blood-vessel formation) in the breast, this screening method is also suitable for women aged 50 and below and can even detect very early-onset breast cancer. What’s more, the method is pain-free and poses no adverse health risks to patients’ health.

‘Delseni’ was developed in collaboration with a renowned Dutch academic institute, Radboud university, and is currently being trialled in pre-clinical studies.